Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07117890
PHASE2
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Sponsor: Fudan University
View on ClinicalTrials.gov
Summary
This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
Official title: a Study of Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
34
Start Date
2025-02-07
Completion Date
2027-05-30
Last Updated
2025-12-24
Healthy Volunteers
No
Conditions
Interventions
DRUG
sunvozertinib 300mg
sunvozertinib monotherapy, 300mg QD
DRUG
sunvozertinib 200mg
sunvozertinib monotherapy, 200mg QD
Locations (1)
Fudan university shanghai cancer center
Shanghai, China